A sugar found in human milk missed the trial's main immune endpoint
A trial of 2'-fucosyllactose in healthy older adults reported changes in gut bacteria and blood markers, while its main measure of immune response remained unmet.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The trial tested a sugar found in human milk for effects on gut bacteria and immune function in healthy older adults. Its main endpoint, a change in cytokine response, was not met. Reported shifts in bacteria, hormones, and cholesterol concern biological measurements; they do not establish improved immunity or healthier aging.
The abstract does not identify the control condition or give numerical effects and uncertainty. Visual memory findings concern a bacterial-response subgroup, rather than an established benefit for all participants.
The main outcome remained unmet
The primary outcome measured a change in cytokine response. That endpoint remained unmet despite reported increases in Bifidobacterium, a gut bacterial group, insulin, and HDL cholesterol. These changes should be interpreted separately from the main immune result.
Understanding the subgroup finding
Participants classified as Bifidobacterium responders performed better on a visual memory test. Nonresponders more often lacked these bacteria before the intervention. This subgroup result does not establish a memory benefit for all participants or show that bacterial changes caused better performance.
The original publication
A human milk oligosaccharide alters the microbiome, circulating hormones, and metabolites in a randomized controlled trial of older adults.
Carter MM, Demis D, Perelman D et al.
Cell Rep Med · 2025
- PubMed ID
- 40738103
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.